Results 301 to 310 of about 1,782,146 (327)

Induction Camrelizumab and Modified TPF (Nab‐Paclitaxel, Cisplatin, and S‐1) in Locoregionally Advanced Nasopharyngeal Carcinoma

open access: yesCancer Science, Volume 116, Issue 6, Page 1616-1626, June 2025.
ABSTRACT Induction chemo‐immunotherapy has emerged as a potential treatment option for locoregionally advanced nasopharyngeal carcinoma (LANPC). This study aimed to evaluate the efficacy and safety of camrelizumab combined with modified TPF (nab‐paclitaxel, cisplatin, and S‐1) as induction chemo‐immunotherapy in LANPC.
Yi‐Feng Yu   +5 more
wiley   +1 more source

Pneumocystis jirovecii pneumonia–Immune reconstitution inflammatory syndrome: A review of published cases

open access: yesHIV Medicine, Volume 26, Issue 6, Page 839-848, June 2025.
Abstract Background Immune reconstitution inflammatory syndrome (IRIS) can occur in patients with HIV after commencing antiretroviral therapy. Tuberculosis–IRIS is the most common, and Pneumocystis jirovecii pneumonia (PJP)–IRIS accounts for only 2.7%–4% of IRIS cases.
Natasha Marcella Vaselli   +3 more
wiley   +1 more source

Peri-Implant Epstein-Barr Virus (+) Mucocutaneous Ulcer in an Immunocompetent Patient: Case Report and Review of the Literature. [PDF]

open access: yesClin Implant Dent Relat Res
Lafuente-Ibáñez de Mendoza I   +5 more
europepmc   +1 more source

Molecular Characterization of Epstein - Barr virus Based on EBNA3C Protein among Hematopoietic Stem Cell Transplant Recipients in Jordan. [PDF]

open access: yesMediterr J Hematol Infect Dis
Athamneh RY   +5 more
europepmc   +1 more source

Viral contamination in cell culture: analyzing the impact of Epstein Barr virus and Ovine Herpesvirus 2. [PDF]

open access: yesFront Microbiol
Bastawecy IM   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy